SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending with high anticipation ahead of its earnings report, as the community eagerly discusses whether its AI advancements like Gemini and strong cloud growth can deliver a market-saving beat amidst broader tech sector uncertainty, or if a 'sell the news' reaction is likely after its recent significant run.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending ahead of its upcoming earnings report, as the community debates whether its strong AI momentum with Gemini and Waymo will drive a market rally or if a "sell the news" reaction will trigger a broader tech sector pullback following its significant run.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is heavily discussed ahead of its earnings report, with community sentiment divided between optimists highlighting its vast user base and potential for monetization amidst oversold conditions, and skeptics focusing on its consistent profitability challenges, intense competition, and management issues compounded by growing concerns over social media restrictions for minors.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending after its strong Q4 earnings were overshadowed by conservative Q1 guidance, particularly concerning AI chip sales to China, triggering a significant sell-off across the semiconductor sector. The community is divided between those buying the dip, seeing an overreaction given long-term AI demand, and others who view the guidance as a necessary reality check on high valuations.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is the subject of intense investor conversation, grappling with concerns over its premium valuation and market reactions to guidance, even as its foundational technology is critical for advancing AI, robotics, and data center compute. The community is deeply split, with many highlighting its expanding "Physical AI" division and strategic position, while others remain skeptical about its near-term execution and market performance.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is actively discussed after its strong financial report, with the community balancing optimism for its AI and automotive growth against concerns regarding guidance and persistent competitive pressures in the semiconductor market.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following mixed earnings, where an EPS beat was overshadowed by slightly missed revenue and lowered guidance, causing a sharp decline in share price. The community is actively debating whether this presents an oversold buying opportunity or reflects ongoing concerns about growth and tariff impacts.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is surging due to strong earnings and an elevated 2026 outlook, fueled by robust demand for its Mounjaro and Zepbound drugs, solidifying its competitive leadership in the rapidly expanding GLP-1 market. The community is actively discussing its sustained growth trajectory and strategic initiatives, including a major AI partnership.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after announcing the acquisition of two new strategic sites that more than double its digital and power capacity to 2.8 GW, significantly advancing its pivot into AI and high-performance computing. This transformative news is fueling community discussion about a potential short squeeze and a major re-valuation of the stock, with many expecting further decoupling from Bitcoin's performance.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

The Schwab US Dividend Equity ETF ($SCHD) is trending due to its strong recent performance and resilience on broader market red days, leading to community discussions about a rotation from high-beta growth stocks into value and dividend plays as investors seek defensive positions. Long-term holders are celebrating its "money printing" nature and perceived "AI hedge" capabilities, though some still debate its sustainability after prior periods of underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen (NASDAQ:OCGN) Trading 12.4% Higher - Time to Buy?

Ocugen (NASDAQ:OCGN) Trading Up 12.4% - What's Next...

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.read more...

Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Ocugen in a report on Tuesday...

Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the target of a large decline in short interest in December. As of December 31st, there was short interest totaling 46,392,427 shares, a decline of...

Ocugen Stock Is Surging Today: What's Driving The Action?

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.read more...

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, with no serious safety issues.read more...

Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ocugen (NASDAQ:OCGN) Shares Up 9% - Time to Buy?

Ocugen (NASDAQ:OCGN) Trading 9% Higher - Should You Buy...

<ul class="summary-bullets"><li>Ocugen stated that, in six patients with gradable Fundus Auto Fluorescence images, atrophic lesion growth was reduced by 54% in eyes treated with its therapy compared to untreated eyes.</li><li>The company added that lesion expansion was 50% slower in treated eyes than in eyes that did not receive treatment.</li><li>Ocugen also reported that every eye treated with its therapy showed either stabilization or improvement in visual acuity.</li></ul>Ocugen Inc. (OCGN) shares rose nearly 3% pre-market on Monday after the company announced results in its gene therapy trial for Stargardt patients with no options.Ocugen announced positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease. This disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined, the company said.<h2 class="st-heading-2">Ocugen Trial Update</h2>In its Phase 1 GARDian1 trial update, Ocugen reported that, among six patients with gradable Fundus Auto Fluorescence images, atrophic lesion growth was reduced by 54% in eyes treated with its therapy compared to untreated eyes.The company added that lesion expansion was 50% slower in treated eyes compared to those that did not receive the treatment. Ocugen also reported that every eye treated with its therapy showed either stabilization or improvement in visual acuity.Lastly, the company stated that there were no drug-related serious adverse events, nor were adverse events of special interest observed.<h2 class="st-heading-2">Retail Upbeat</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OCGN">Ocugen</a> edged up over the past 24 hours, hovering in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.One bullish user stated that traders were not as excited about Ocugen as they should be.<stembedurl>https://stocktwits.com/HandsomeBull1/message/641502007</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is up 11% year-to-date and 81% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/abvx-soars-pre-market-on-reports-of-17-5-billion-eli-lilly-takeover-interest/cmU9zJNR4E2">ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder

Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined.

Equity

Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?

Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.06	--	--	N/A
Q3 '25	-$0.06	-$0.07	-25.00%	MISSED
Q2 '25	-$0.06	-$0.05	10.71%	BEAT
Q1 '25	-$0.06	-$0.05	13.04%	BEAT
Q4 '24	-$0.05	-$0.05	6.25%	BEAT

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest OCGN News

OCGNOcugen Inc